A First Prenatal Visit at Ten Weeks for a 37-Year-Old: Choosing Among Aneuploidy Screening Options With Her, and Why Low-Dose Aspirin Starts at Twelve Weeks
[Student Name]
University of Phoenix
NRP/563: Management of Women's Health Issues
Week 5 Assignment
[Instructor Name]
[Date]
The patient is a composite written for a model paper.
Ms. A., a 37-year-old accountant, is 10 weeks pregnant by her last menstrual period, confirmed by ultrasound. Her first child was born four years ago by uncomplicated vaginal delivery. She has a BMI of 31 and no chronic medical conditions. Her mother had preeclampsia. She takes a prenatal vitamin. This paper describes her first prenatal visit and two key decisions.
The Initial Prenatal Visit
The first visit establishes dating, screens for conditions that affect pregnancy and begins education. I review her obstetric, medical, family and social history; perform a physical examination, including blood pressure, weight and a pelvic examination; and order the usual first-trimester laboratory work, covering blood group, anemia, immunity to rubella and chickenpox, infections that can pass to the baby and a urine culture, plus early glucose testing because of her age and weight. Cervical screening is current. I review nutrition, activity, weight gain goals, medications and substance avoidance.
Decision 1: Aneuploidy Screening
ACOG recommends that aneuploidy screening or diagnostic testing be offered to all pregnant patients regardless of age, and that patients be counseled about the options, their detection rates, false-positive rates, limitations and the choice to decline (American College of Obstetricians and Gynecologists et al., 2020). Options include cell-free DNA screening, serum screening combined with nuchal translucency and diagnostic testing with chorionic villus sampling or amniocentesis.
What Cell-Free DNA Offers
Cell-free DNA screening analyzes placental DNA fragments in the mother's blood. Norton et al. (2015) studied 15,841 women in a routine screening population with a mean age of 30.7 and found that cell-free DNA detected all 38 cases of trisomy 21, compared with 30 of 38 with standard screening, with a false-positive rate of 0.06% compared with 5.4%. Cell-free DNA had a higher positive predictive value as well.
A screening test with a tiny false-positive rate still gives probabilities, not answers, and the counseling has to say so.
The Limits of Screening
Cell-free DNA is a screening test. A positive result requires diagnostic testing to confirm, because false positives occur and because the DNA comes from the placenta, which can differ from the fetus. It screens mainly for common trisomies and some sex chromosome conditions, not for all genetic or structural problems. A low fetal fraction, more common with higher BMI, can make results uninterpretable.
Her Decision
Ms. A. values information but does not want an invasive test unless a screen is positive. She chooses cell-free DNA screening, to be drawn today, along with a first-trimester ultrasound for nuchal translucency and early anatomy. I explain that she can decline any test at any time and that results do not obligate any decision.
Decision 2: Preeclampsia Risk and Aspirin
Federal preventive guidance supports a daily 81 mg aspirin as preventive medication for preeclampsia after 12 weeks of gestation in people at high risk for preeclampsia (U.S. Preventive Services Task Force et al., 2021). High-risk factors include a history of preeclampsia, multifetal gestation, chronic hypertension, diabetes, kidney disease and autoimmune disease; moderate-risk factors include first pregnancy, obesity, family history of preeclampsia, age 35 or older, Black race as a marker of social and structural risk, low income and certain personal history factors. The Task Force suggests aspirin for people with more than one moderate-risk factor.
Applying It to Ms. A.
She has no high-risk factors but three moderate ones: age 37, BMI of 31 and her mother's preeclampsia. That places her in the group for whom aspirin is suggested. I recommend 81 mg daily starting at 12 weeks, ideally before 16 weeks, continued until delivery, and she agrees.
Why Start at Twelve Weeks
Preeclampsia is thought to begin with abnormal development of the placenta early in pregnancy. Starting aspirin after 12 weeks, when placental development is under way, aims to influence that process while avoiding first-trimester exposure.
Why Age Alone No Longer Decides
For decades, invasive diagnostic testing was offered mainly to women 35 and older because the risk of chromosomal conditions rises with maternal age. Current guidance recommends offering screening and diagnostic options to everyone, because younger women have most babies with chromosomal conditions simply because they have most babies, and because screening has improved (American College of Obstetricians and Gynecologists et al., 2020). At 37, Ms. A.'s risk is higher than a younger woman's, but her choice is still hers.
Diagnostic Testing as an Option
Chorionic villus sampling at 10 to 13 weeks or amniocentesis after 15 weeks can diagnose chromosomal conditions directly, with a small risk of miscarriage. Some patients prefer to skip screening and go straight to diagnosis; others prefer no testing at all. I describe each without steering her, since the right choice depends on how she would use the information.
What a Positive Result Would Mean
If her cell-free DNA result were positive for trisomy 21, I would explain that it is a screening result, refer her for genetic counseling and offer diagnostic testing before any decision. The high positive predictive value in the trial is reassuring, but it still falls short of certainty (Norton et al., 2015).
Weight Gain and Nutrition
With a BMI of 31, the recommended total weight gain is about 5 to 9 kilograms. I refer her to a dietitian and suggest 150 minutes a week of moderate activity, which is safe in an uncomplicated pregnancy and may reduce the risk of gestational diabetes.
Education
I discuss warning signs of pregnancy complications: bleeding, severe abdominal pain, severe headache, visual changes, swelling of the face or hands and decreased fetal movement later in pregnancy. I recommend influenza vaccination now and Tdap at 27 to 36 weeks.
Her Previous Pregnancy
Her first pregnancy was uncomplicated, which is reassuring, though it does not remove the risks linked to her age and weight. I ask about her previous labor, breastfeeding and any postpartum mood symptoms, since a history of postpartum depression would change planning. She had none, and she screens negative for depression today.
Aspirin Safety
She asks whether aspirin could harm the baby. At 81 mg, aspirin has not been associated with fetal harm in the trials reviewed by the Task Force, and the benefit for people at increased risk outweighs the small bleeding risk (U.S. Preventive Services Task Force et al., 2021). She will stop it if bleeding occurs and tell her delivery team she takes it.
Follow-Up
Return in four weeks to review results, with visits every four weeks until 28 weeks.
Conclusion
At Ms. A.'s first prenatal visit, standard evaluation was combined with two evidence-based decisions. Offered aneuploidy screening as ACOG recommends, she chose cell-free DNA, which trial data show detects trisomy 21 with far fewer false positives than standard screening, after counseling on its limits. With three moderate risk factors for preeclampsia, she will start low-dose aspirin at 12 weeks, following the USPSTF recommendation.
References
American College of Obstetricians and Gynecologists' Committee on Practice Bulletins-Obstetrics, Committee on Genetics, & Society for Maternal-Fetal Medicine. (2020). Screening for fetal chromosomal abnormalities: ACOG practice bulletin, number 226. Obstetrics & Gynecology, 136(4), e48-e69. https://doi.org/10.1097/AOG.0000000000004084
Norton, M. E., Jacobsson, B., Swamy, G. K., Laurent, L. C., Ranzini, A. C., Brar, H., Tomlinson, M. W., Pereira, L., Spitz, J. L., Hollemon, D., Cuckle, H., Musci, T. J., & Wapner, R. J. (2015). Cell-free DNA analysis for noninvasive examination of trisomy. New England Journal of Medicine, 372(17), 1589-1597. https://doi.org/10.1056/NEJMoa1407349
U.S. Preventive Services Task Force, Davidson, K. W., Barry, M. J., Mangione, C. M., Cabana, M., Caughey, A. B., Davis, E. M., Donahue, K. E., Doubeni, C. A., Kubik, M., Li, L., Ogedegbe, G., Pbert, L., Silverstein, M., Simon, M. A., Stevermer, J., Tseng, C.-W., & Wong, J. B. (2021). Aspirin use to prevent preeclampsia and related morbidity and mortality: US Preventive Services Task Force recommendation statement. JAMA, 326(12), 1186-1191. https://doi.org/10.1001/jama.2021.14781
How this NRP 563 Week 5 example is structured
The NRP/563 Week 5 work usually addresses normal pregnancy and prenatal care. This paper covers the first prenatal visit, with two decisions examined in depth, genetic screening and preeclampsia prevention, each grounded in current evidence and the patient's values. Students search this week as NRP 563 Week 5, NRP563 Wk 5 or NRP/563 Wk 5; all three are the same assignment.
NRP/563 Week 5 questions, answered
What does NRP/563 Week 5 usually ask for?
Many sections ask students to plan prenatal care for a normal pregnancy, including the initial visit, screening tests and education.
Should all pregnant patients be offered aneuploidy screening?
Yes. ACOG recommends offering aneuploidy screening or diagnostic testing to all pregnant patients regardless of age, after counseling about options.
Who should take low-dose aspirin in pregnancy?
The USPSTF recommends 81 mg of aspirin daily after 12 weeks of gestation for people at high risk of preeclampsia.
Write yours, or have the desk draft it
This paper is an original model document written by our desk, not a submitted student paper and not an official University of Phoenix document. Read it for the moves, then write your own to the instructions in your classroom. If you want one built to your exact prompt and rubric, the first custom sample is free and arrives in 24 to 48 hours.